argenx SE (ARGNF)

OTCMKTS · Delayed Price · Currency is USD
547.60
+0.42 (0.08%)
At close: Jul 2, 2025
46.61%
Market Cap 33.25B
Revenue (ttm) 2.64B
Net Income (ttm) 1.06B
Shares Out n/a
EPS (ttm) 15.94
PE Ratio 31.25
Forward PE 34.38
Dividend n/a
Ex-Dividend Date n/a
Volume 10
Average Volume 22
Open 547.60
Previous Close 547.18
Day's Range 547.60 - 547.60
52-Week Range 442.89 - 697.42
Beta 0.04
RSI 51.33
Earnings Date Jul 31, 2025

About argenx SE

argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYGART and VYGART HYTRULO to treat generalized myasthenia gravis (gMG), immune thrombocytopenia (ITP), and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative and ocular gMG, thyroid eye diseases, ITP, myositis, Sjögren’s disease, lupus nephropathy, systemic sclerosis, ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2008
Employees 1,599
Stock Exchange OTCMKTS
Ticker Symbol ARGNF
Full Company Profile

Financial Performance

Financial Statements

News

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of argenx SE - ARGX

NEW YORK , July 7, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  argenx SE ("argenx" or the "Company") (NASDAQ: ARGX). Such investors are advised to contact Dan...

1 day ago - PRNewsWire

Here's How Much You Would Have Made Owning argenx Stock In The Last 5 Years

argenx (NASDAQ: ARGX) has outperformed the market over the past 5 years by 2.79% on an annualized basis producing an average annual return of 17.38%. Currently, argenx has a market capitalization of ...

6 days ago - Benzinga

FDA Flags Major Safety Concerns For Argenx's Nerve Disorder Drug, Stock Falls

Argenx SE (NASDAQ: ARGX) stock is trading lower on Monday after the U.S. Food and Drug Administration (FDA) signaled serious risks/safety identified by the reporting system for Vyvgart Hytrulo (efgar...

8 days ago - Benzinga

FDA Flags Major Safety Concerns For Argenx's Nerve Disorder Drug, Stock Falls

Argenx SE ARGX stock is trading lower on Monday after the U.S. Food and Drug Administration (FDA) signaled serious risks/safety identified by the reporting system for Vyvgart Hytrulo (efgartigimod alf...

8 days ago - Benzinga

argenx Announces European Commission Approval of VYVGART Subcutaneous Injection for Chronic Inflammatory Demyelinating Polyneuropathy

VYVGART ® SC, first-and-only IgG Fc-antibody fragment which specifically targets the neonatal Fc receptor (FcRn), now approved for use in Europe for CIDP Approval based on ADHERE clinical trial, the l...

18 days ago - GlobeNewsWire

$1000 Invested In This Stock 5 Years Ago Would Be Worth This Much Today

argenx (NASDAQ: ARGX) has outperformed the market over the past 5 years by 6.27% on an annualized basis producing an average annual return of 20.6%. Currently, argenx has a market capitalization of $...

22 days ago - Benzinga

argenx Presents New Efgartigimod Data at EULAR 2025 Highlighting Positive Phase 2 Proof-of-Concept Results in Myositis and Sjogren's Disease

ALKIVIA data demonstrate significant improvement in muscle strength and physical function in myositis patients treated with efgartigimod RHO data show efgartigimod achieved sustained reduction in auto...

4 weeks ago - Benzinga

argenx Presents New Efgartigimod Data at EULAR 2025 Highlighting Positive Phase 2 Proof-of-Concept Results in Myositis and Sjogren's Disease

ALKIVIA data demonstrate significant improvement in muscle strength and physical function in myositis patients treated with efgartigimod RHO data show efgartigimod achieved sustained reduction in auto...

4 weeks ago - GlobeNewsWire

argenx to Present at Goldman Sachs 46th Annual Global Healthcare Conference

June 3, 2025 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today anno...

5 weeks ago - GlobeNewsWire

argenx Announces Results of Annual General Meeting of Shareholders

May 28, 2025 – 10:01 PM C ET

5 weeks ago - GlobeNewsWire

Hot Picks in biotech: argenx, Scholar Rock & Kiniksa

David Nierengarten, senior analyst at Wedbush, shares his hot picks in the biotech sector: argenx SE, Scholar Rock and Kiniksa Pharmaceuticals.

7 weeks ago - BNN Bloomberg

Eli Lilly, Affirm And Regeneron Are Among Top 12 Large-Cap Losers Last Week (May 5-May 9): Are The Others In Your Portfolio?

These large-cap stocks were the worst performers in the last week. Are they in your portfolio? argenx SE (NASDAQ: ARGX) shares tumbled 15.40% after the company reported first-quarter results . Vertex...

2 months ago - Benzinga

Argenx plunges after Q1 revenue miss

2 months ago - Seeking Alpha

Argenx Beats Sales Expectations — But Not By Enough — And Shares Tumble

Argenx stock tumbled Thursday after its drug, Vyvgart, beat sales expectations. But the beat wasn't strong enough for investors.

2 months ago - Investor's Business Daily

Earnings Scheduled For May 8, 2025

Companies Reporting Before The Bell • Sempra (NYSE: SRE) is likely to report quarterly earnings at $1.32 per share on revenue of $3.92 billion. • Warner Music Gr (NASDAQ: WMG) is projected to report...

2 months ago - Benzinga

argenx Reports First Quarter 2025 Financial Results and Provides Business Update

$790 million in first quarter global product net sales First patients treated with VYVGART Hytrulo pre-filled syringe for self-injection in US and Germany CIDP global expansion with positive CHMP opin...

2 months ago - GlobeNewsWire

A Look Into argenx Inc's Price Over Earnings

In the current session, the stock is trading at $622.93, after a 1.27% increase. Over the past month, argenx Inc. (NASDAQ: ARGX) stock increased by 10.42% , and in the past year, by 62.84% . With per...

2 months ago - Benzinga

HALOZYME RAISES 2025 FINANCIAL GUIDANCE RANGES AND REPORTS STRONG FIRST QUARTER 2025 RESULTS

Announcing New $250M Share Repurchase Total Revenue Increased 35% YOY to $265 million and Royalty Revenue Increased 39% YOY to $168 million Net Income Increased 54% YOY to $118 million ; Adjusted EBIT...

2 months ago - Benzinga